↓ Skip to main content

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.

Overview of attention for article published in Journal of Clinical Oncology, May 2000
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

news
1 news outlet
guideline
1 clinical guideline source

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Published in
Journal of Clinical Oncology, May 2000
DOI 10.1200/jco.2000.18.9.1921
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 7 21%
Other 4 12%
Student > Master 3 9%
Professor > Associate Professor 3 9%
Student > Bachelor 2 6%
Other 7 21%
Unknown 8 24%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 17 50%
Biochemistry, Genetics and Molecular Biology 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Agricultural and Biological Sciences 1 3%
Immunology and Microbiology 1 3%
Other 0 0%
Unknown 11 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2023.
All research outputs
#6,769,035
of 34,365,356 outputs
Outputs from Journal of Clinical Oncology
#13,936
of 32,345 outputs
Outputs of similar age
#13,362
of 59,904 outputs
Outputs of similar age from Journal of Clinical Oncology
#35
of 89 outputs
Altmetric has tracked 34,365,356 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,345 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 59,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.